openPR Logo
Press release

Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16) - Pipeline Review, H1 2017

06-26-2017 04:50 PM CET | Health & Medicine

Press release from: Pharmaceutical Market Reports - MRH

Market Research HUB

Market Research HUB

According to the recently added report 'Tumor Necrosis Factor Receptor Superfamily Member 16 - Pipeline Review, H1 2017'; Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Request Free Sample Report - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1177503

Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Tumor necrosis factor receptor superfamily member 16 plays a role in the regulation of the translocation of GLUT4 to the cell surface in adipocytes and skeletal muscle cells in response to insulin, probably by regulating RAB31 activity, and thereby contributes to the regulation of insulin-dependent glucose uptake. Low affinity receptor which can bind to NGF, BDNF, NT-3, and NT-4.

The report 'Tumor Necrosis Factor Receptor Superfamily Member 16 - Pipeline Review, H1 2017' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II and Preclinical stages are 1, 1 and 3 respectively. Report covers products from therapy areas Central Nervous System, Dermatology, Infectious Disease, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Alzheimer's Disease, Chemotherapy Induced Peripheral Neuropathy, Chronic Pain, Corneal Ulcer (Ulcerative Keratitis/ Eyesore), HIV Related Neurological Diseases, Huntington Disease, Keratoconjunctivitis sicca (Dry Eye), Open-Angle Glaucoma, Osteoarthritis, Persistent Corneal Epithelial Defects, Retinitis Pigmentosa (Retinitis), Spinal Cord Injury, Traumatic Brain Injury and Wounds.

Browse Full Report with TOC - http://www.marketresearchhub.com/report/tumor-necrosis-factor-receptor-superfamily-member-16-low-affinity-neurotrophin-receptor-p75ntr-or-low-affinity-nerve-growth-factor-receptor-or-gp80-lngfr-or-p75-icd-or-tnfrsf16-or-cd271-or-ngfr-pipeline-review-h1-2017-report.html

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an Enquiry - http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1177503

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email : press@marketresearchhub.com
Website : http://www.marketresearchhub.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16) - Pipeline Review, H1 2017 here

News-ID: 595994 • Views: 258

More Releases from Pharmaceutical Market Reports - MRH

Global Active Pharmaceutical Ingredients Market Size, Growth, Share, Trends and …
Market Research Hub includes new market research report "Global Active Pharmaceutical Ingredients Market Research Report 2017-2022 by Players, Regions, Product Types & Applications" to its huge collection of research reports. The global Active Pharmaceutical Ingredients market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Request Free Sample Report -
Global and Chinese Carfentanil Expedient Market Outlook and Profitable Forecasts …
The carfentanil market is witnessing huge developments in the veterinary and other chemical research sectors. Looking into this development, a new report has been added to the vast online repository of Market Research Hub (MRH), with the title ‘’Global and Chinese Carfentanil Market Outlook 2017-2022‘’. The study offers a precise evaluation of the most positive business factors such as biggest players and regions; as well as a prospective forecast till
Global Propofol Sales Market Size, Share, Growth, Trends and Forecast
According to the report "Global Propofol Sales Market Report 2017" added by Market Research HUB, the global Propofol market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate
Global Mammalian Cell Culture Sales Market Size, Share, Trends and Forecast
According to the report "Global Mammalian Cell Culture Sales Market Report 2017" added by Market Research HUB, the global Mammalian Cell Culture market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market

All 5 Releases


More Releases for Receptor

Interleukin Receptor Modulators Therapeutics - Pipeline Analysis 2019
Interleukin receptors are a group of cytokine receptors that are expressed by leukocytes. Interleukin receptors play an important role in the functioning of the immune system. However, with complete knowledge of their role in pathogenesis of different diseases from allergic reactions to autoimmune disorders and even cancer makes these interleukin receptors an attractive target among different available treatment modalities. Download the sample report @ https://www.pharmaproff.com/request-sample/1204 Immune-modulatory role of interleukins as well
Tumor Necrosis Factor Receptor
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Tumor Necrosis Factor - Pipeline Review, H2 2017” Tumor Necrosis Factor Overview Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Gh …
"The Report Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Pi …
ReportsWorldwide has announced the addition of a new report title Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H2 2017'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 11 molecules. Out of which approximately
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Pi …
ReportsWorldwide has announced the addition of a new report title Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H2 2017'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 11 molecules. Out of which approximately
Estrogen Receptor Market Pipeline Review, H2 2017
"The Report Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 22 molecules.